Brookline Capital Management Equities Analysts Lower Earnings Estimates for Aileron Therapeutics, Inc. (NASDAQ:ALRN)

Aileron Therapeutics, Inc. (NASDAQ:ALRN) – Brookline Capital Management lowered their FY2024 earnings estimates for Aileron Therapeutics in a note issued to investors on Wednesday, August 14th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will earn ($1.35) per share for the year, down from their prior estimate of ($1.24). Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aileron Therapeutics’ current full-year earnings is ($1.36) per share. Brookline Capital Management also issued estimates for Aileron Therapeutics’ Q4 2024 earnings at ($0.15) EPS and FY2025 earnings at ($1.02) EPS.

Aileron Therapeutics Stock Up 11.6 %

Shares of NASDAQ:ALRN opened at $2.40 on Monday. The business’s 50 day moving average is $2.68 and its 200 day moving average is $4.01. The stock has a market cap of $51.88 million, a P/E ratio of -0.72 and a beta of 2.23. Aileron Therapeutics has a 52-week low of $1.01 and a 52-week high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last issued its earnings results on Wednesday, August 14th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.20).

Insiders Place Their Bets

In other news, major shareholder Of Texas/Texas Am I. University sold 9,577 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $3.30, for a total transaction of $31,604.10. Following the transaction, the insider now owns 1,768,250 shares in the company, valued at $5,835,225. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, major shareholder Of Texas/Texas Am I. University sold 9,577 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $3.30, for a total value of $31,604.10. Following the completion of the sale, the insider now owns 1,768,250 shares in the company, valued at approximately $5,835,225. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $3.25, for a total transaction of $30,361.50. Following the completion of the sale, the insider now directly owns 1,753,156 shares of the company’s stock, valued at approximately $5,697,757. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,557 shares of company stock worth $109,966. 5.57% of the stock is currently owned by company insiders.

Institutional Trading of Aileron Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ALRN. Nantahala Capital Management LLC lifted its stake in shares of Aileron Therapeutics by 82.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after purchasing an additional 209,367 shares during the last quarter. Warberg Asset Management LLC purchased a new stake in shares of Aileron Therapeutics during the second quarter valued at about $86,000. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at about $4,925,000. Texas Capital Bank Wealth Management Services Inc grew its position in shares of Aileron Therapeutics by 65.9% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock worth $174,000 after buying an additional 10,398 shares during the last quarter. Finally, Sigma Planning Corp purchased a new position in shares of Aileron Therapeutics in the 4th quarter worth approximately $51,000. Institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).